Haemonetics (HAE) Enterprise Value (2009 - 2026)

Haemonetics has reported Enterprise Value for 18 years, with the latest figure at $3.3 billion in Q2 2026.

• On a quarterly basis, Enterprise Value rose 0.92% year-over-year to $3.3 billion in Q2 2026; TTM through Jun 2026 was $3.3 billion, a 0.92% increase from a year earlier, with the FY2026 full-year figure at $2.2 billion, down 19.71% from the prior year.
• Enterprise Value was $3.3 billion for Q2 2026 at Haemonetics, up from $2.2 billion in the prior quarter.
• The five-year high for Enterprise Value was $4.2 billion in Q3 2023, with the low at $2.0 billion in Q3 2025.
• Average Enterprise Value over 5 years is $3.4 billion, with a median of $3.5 billion recorded in 2022.
• The largest YoY upside for Enterprise Value was 51.31% in 2022 against a maximum downside of 57.68% in 2022.
• Over 5 years, Enterprise Value stood at $3.7 billion in 2022, then climbed by 10.82% to $4.1 billion in 2023, then declined by 13.81% to $3.6 billion in 2024, then slipped by 5.03% to $3.4 billion in 2025, then fell by 3.09% to $3.3 billion in 2026.
• The last three Enterprise Value figures came in at $3.3 billion (Q2 2026), $2.2 billion (Q1 2026), and $3.4 billion (Q4 2025), per Business Quant data.